methyl (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hept-6-enoate | 1093645-18-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: methyl (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hept-6-enoate
• 英文别名: methyl (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)hept-6-enoate
• CAS: 1093645-18-1
• 化学式: C₂₃H₂₅NO₄
• 分子量: 379.456
• InChiKey: HZLJSMLISASALY-OAQYLSRUSA-N

物化性质

• 沸点：
  558.5±50.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hept-6-enoate 在 盐酸 、 水 、 Fmoc-Val-OMe 作用下， 以 1,4-二氧六环 为溶剂， 以1.2 g的产率得到(2R)-2-[[(9H-芴-9-基甲氧基)羰基]氨基]-6-庚烯酸
  参考文献：
  名称：

  Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-β particle formation in vitro

  摘要：

  Reverse cholesterol transport (RCT) is believed to be the primary mechanism by which HDL and its major protein apoA-I protect against atherosclerosis. Starting from the inactive 22-amino acid peptide representing the consensus sequence of the class A amphipathic helical repeats of apoA-I, we designed novel peptides able to mobilize cholesterol from macrophages in vitro, and to stimulate the formation of 'nascent HDL' particles, with potency comparable to the entire apoA-I protein. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.128
• 作为产物：
  描述：

  L-缬氨酸甲酯 、 methyl (2R)-2-aminohept-6-enoate 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 以 二氯甲烷 为溶剂， 生成 methyl (2R)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hept-6-enoate 、 Fmoc-Val-OMe
  参考文献：
  名称：

  Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-β particle formation in vitro

  摘要：

  Reverse cholesterol transport (RCT) is believed to be the primary mechanism by which HDL and its major protein apoA-I protect against atherosclerosis. Starting from the inactive 22-amino acid peptide representing the consensus sequence of the class A amphipathic helical repeats of apoA-I, we designed novel peptides able to mobilize cholesterol from macrophages in vitro, and to stimulate the formation of 'nascent HDL' particles, with potency comparable to the entire apoA-I protein. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.128

文献信息

• APOA-1 PEPTIDE MIMETICS
  申请人：Bianchi Elisabetta

  公开号：US20110046056A1

  公开（公告）日：2011-02-24

  The invention relates to peptide mimetics for treating disorders associated with hypercholesterolemia and cardio-vascular disease. In particular, the invention relates to peptides that mimic the activity of apolipoprotein A-I (Apo AI).

  本发明涉及用于治疗与高胆固醇血症和心血管疾病有关的疾病的肽类类似物。具体而言，本发明涉及模拟载脂蛋白A-I（Apo AI）活性的肽类。
• Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-β particle formation in vitro
  作者：Raffaele Ingenito、Charlotte Burton、Annunziata Langella、Xun Chen、Karolina Zytko、Antonello Pessi、Jun Wang、Elisabetta Bianchi

  DOI：10.1016/j.bmcl.2009.10.128

  日期：2010.1

  Reverse cholesterol transport (RCT) is believed to be the primary mechanism by which HDL and its major protein apoA-I protect against atherosclerosis. Starting from the inactive 22-amino acid peptide representing the consensus sequence of the class A amphipathic helical repeats of apoA-I, we designed novel peptides able to mobilize cholesterol from macrophages in vitro, and to stimulate the formation of 'nascent HDL' particles, with potency comparable to the entire apoA-I protein. (C) 2009 Elsevier Ltd. All rights reserved.